Skip to Main Content

Hello, everyone, and how are you this cold morning? The middle of the week has arrived, as you may know, so why not celebrate with a delicious cup of stimulation? After all, you made is this far, which is a likely sign of surviving another few days. And of course, no prescription is required, which is a good thing. And while you drink up, you can peruse some of the tidbits we have assembled to help you start the day. Meanwhile, we have a modified schedule today, thanks to a presentation we are scheduled to make. Wish us luck. Hope you conquer the world and, as always, do keep in touch …

Roche (RHHBY) is halting two late-stage clinical trials of its crenezumab drug for early Alzheimer’s disease after an interim analysis indicated it was unlikely to hit its primary goal, Reuters says. The announcement by Roche, which has been working on the product with AC Immune, marks the latest high-profile failure of an Alzheimer’s drug following the 2016 flop of an experimental medicine from Eli Lilly (LLY). The failures have undermined conviction in the beta amyloid hypothesis, in which a protein forms plaques in the brain and likely plays a pivotal role in the disorder.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!